Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Rafal, Goraczniak"'
Autor:
Darren R. Carpizo, Samuel I. Gunderson, Eric S. Ho, Mark A. Brenneman, Samuel Kogan, Kristen Donohue, Rafal Goraczniak, Xin Yu, Lan Yi, Crissy Dudgeon, Ashley T. Tsang
Supplemental Figures 1-4 with figure legends and Supplemental Table
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24bf9136fc16c0f2a96916f81faad83f
https://doi.org/10.1158/1535-7163.22508458
https://doi.org/10.1158/1535-7163.22508458
Autor:
Rafal Goraczniak, Brian A Wall, Mark A Behlke, Kim A Lennox, Eric S Ho, Nikolas H Zaphiros, Christopher Jakubowski, Neil R Patel, Steven Zhao, Carlo Magaway, Stacey A Subbie, Lumeng Jenny Yu, Stephanie LaCava, Kenneth R Reuhl, Suzie Chen, Samuel I Gunderson
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 2, Iss C (2013)
U1 Adaptor is a recently discovered oligonucleotide-based gene-silencing technology with a unique mechanism of action that targets nuclear pre-mRNA processing. U1 Adaptors have two distinct functional domains, both of which must be present on the sam
Externí odkaz:
https://doaj.org/article/05875fbc03754cd9bb797287478d6134
Autor:
Eric S. Ho, Mark Brenneman, Crissy Dudgeon, Rafal Goraczniak, Lan Yi, Xin Yu, Samuel I. Gunderson, Ashley T. Tsang, Kristen Donohue, Darren R. Carpizo, Samuel Kogan
Publikováno v:
Molecular Cancer Therapeutics. 16:1445-1455
Targeting KRAS and MYC has been a tremendous challenge in cancer drug development. Genetic studies in mouse models have validated the efficacy of silencing expression of both KRAS and MYC in mutant KRAS-driven tumors. We investigated the therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86628cf17a51150e893649cc5f236479
https://doi.org/10.1158/1535-7163.mct-16-0867
https://doi.org/10.1158/1535-7163.mct-16-0867
Autor:
Ashley T, Tsang, Crissy, Dudgeon, Lan, Yi, Xin, Yu, Rafal, Goraczniak, Kristen, Donohue, Samuel, Kogan, Mark A, Brenneman, Eric S, Ho, Samuel I, Gunderson, Darren R, Carpizo
Publikováno v:
Molecular cancer therapeutics. 16(8)
Targeting KRAS and MYC has been a tremendous challenge in cancer drug development. Genetic studies in mouse models have validated the efficacy of silencing expression of both KRAS and MYC in mutant KRAS driven tumors. We investigated the therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5cc36748d209c7d67326049ce98919d8
https://pubmed.ncbi.nlm.nih.gov/28377488
https://pubmed.ncbi.nlm.nih.gov/28377488
Publikováno v:
Nature Biotechnology. 27:257-263
We describe a gene silencing method that employs a mechanism of action distinct from those of antisense and RNA interference. U1 Adaptors are bifunctional oligonucleotides with a 'target domain' complementary to a site in the target gene's terminal e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d35c4d6040906359a3fc904c063558d
https://doi.org/10.1038/nbt.1525
https://doi.org/10.1038/nbt.1525
Autor:
Rafal Goraczniak, Samuel I. Gunderson
Publikováno v:
Journal of Biological Chemistry. 283:2286-2296
The 3'-untranslated regions (UTRs) of human papillomavirus 16 (HPV16) and bovine papillomavirus 1 (BPV1) contain a negative regulatory element (NRE) that inhibits viral late gene expression. The BPV1 NRE consists of a single 9-nucleotide (nt) U1 smal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adfa6d70eab4f33c48b909ac3f30fd6f
https://doi.org/10.1074/jbc.m708789200
https://doi.org/10.1074/jbc.m708789200
Autor:
Xin Yu, Samuel I. Gunderson, Darren R. Carpizo, Rafal Goraczniak, Ashley T. Tsang, Mark Brenneman
Publikováno v:
Molecular Cancer Research. 12:B52-B52
Background: While genetic knockdown of RAS in mouse tumor models has substantiated it as a therapeutic target, there is no effective means of targeting RAS currently available in the clinic today. Numerous RNA interference-based studies targeting RAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94cbdbe958197d5d062f17a34d4c37c9
https://doi.org/10.1158/1557-3125.rasonc14-b52
https://doi.org/10.1158/1557-3125.rasonc14-b52
Autor:
Samuel I. Gunderson, Rafal Goraczniak, Ashley T. Tsang, Mark Brenneman, Xin Yu, Darren R. Carpizo
Publikováno v:
Molecular Therapy. 23:S276-S277
Activating mutations of the KRAS gene are key drivers of pancreatic cancer, but the KRAS protein has been refractory to small-molecule drugging. U1 Adaptors are oligonucleotides that enable the U1 small nuclear ribonucleoprotein complex to stably bin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::528f11f7c4ab6434dedc9bf95a53bc21
Autor:
Samuel I. Gunderson, Kim A. Lennox, Stephanie LaCava, Lumeng Jenny Yu, Carlo Magaway, Christopher D Jakubowski, Suzie Chen, Stacey A Subbie, Rafal Goraczniak, Steven Zhao, Brian A. Wall, Mark A. Behlke, Eric S. Ho, Neil Patel, Kenneth R. Reuhl, Nikolas H Zaphiros
Publikováno v:
Molecular Therapy. Nucleic Acids
Molecular Therapy: Nucleic Acids, Vol 2, Iss C (2013)
Molecular Therapy: Nucleic Acids, Vol 2, Iss C (2013)
U1 Adaptor is a recently discovered oligonucleotide-based gene-silencing technology with a unique mechanism of action that targets nuclear pre-mRNA processing. U1 Adaptors have two distinct functional domains, both of which must be present on the sam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15aee98abfefa10c40312a5c2fd85718
Publikováno v:
Molecular Therapy. 24:S102
Many candidate genes are implicated in neurodegenerative disease, but to study potential therapeutic effects of modifying their expression in the central nervous system of animal models has been difficult, often requiring slow, expensive transgenic m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f59bb22a74581ede310bb862ad005aa0
https://doi.org/10.1016/s1525-0016(16)33068-4
https://doi.org/10.1016/s1525-0016(16)33068-4